Regeneron Pharmaceuticals Announces FDA Approval of Pasatru for Adults With Fibrodysplasia Ossificans Progressiva
Regeneron Pharmaceuticals (REGN) announced FDA approval for Pasatru (garetosmab-grts) to treat fibrodysplasia ossificans progressiva (FOP) in adults. The approval follows positive Phase 3 OPTIMA trial results, showing a 90% or greater reduction in new HO lesions and a significant decrease in flare-ups. Pasatru is a monoclonal antibody targeting Activin A, a protein critical in FOP pathology. The drug will be administered intravenously, with a starting dosage of 10 mg/kg once monthly, adjustable
How this was made
The 30-second read
Why it matters
The approval adds a high‑margin, orphan‑drug revenue stream and may boost Regeneron's pipeline credibility.
Market read
Regeneron's stock likely to rally on the approval, with broader implications for rare‑disease biotech valuations.
What to watch
Regeneron's upcoming EU submission and competition from future gene‑editing therapies.
Background
Pasatru is Regeneron's first therapy for fibrodysplasia ossificans progressiva, an ultra‑rare genetic disorder affecting ~900 patients worldwide.
Ticker impact
Regeneron received FDA approval for Pasatru, a new therapy for adults with fibrodysplasia ossificans progressiva.
upward pressure on REGN stock in the short term
First‑time FDA approval for a rare‑disease indication, with limited competition and orphan‑drug pricing potential.
Market effects
strengthens the biotech/rare‑disease therapeutic sector and may lift peers with orphan‑drug pipelines.
U.S. biotech market gains from a high‑profile FDA approval.
Highlights FDA's role in rare‑disease drug approvals, may influence global investors in similar biotech firms.
Counterpoint
Potential reimbursement challenges and limited patient pool could temper long‑term upside.
Key entities
- companyRegeneron Pharmaceuticals, Inc.
US‑listed biotech company developing Pasatru.
- regulatorFDA
U.S. agency granting approval.
